^
Association details:
| Biomarker: | FGFR2-KIAA1217 fusion |
|---|---|
| Cancer: | Cholangiocarcinoma |
| Drug: | zoligratinib (Debio 1347) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
SAFETY AND EFFICACY OF THE SELECTIVE FGFR INHIBITOR DEBIO 1347 IN PHASE 1 STUDY PATIENTS WITH FGFR GENOMICALLY ACTIVATED ADVANCED BILIARY TRACT CANCER
Excerpt:
Three additional iCCA patients (FGFR2 translocations: ROCK1; KIAA1217; DDX21) and one GBC patient (FGFR3-TACC3 translocation) had target lesions regression < 30% and stayed on treatment between 24 – 37 weeks...These results suggest that BTC patients with genomic events, translocations and mutations leading to activation of FGFR2/3, may benefit from treatment with Debio 1347.
